Prognostic factors in postoperative brain metastases derive from non-small cell lung cancer:a retrospective analysis

Author:

Chen Haibin1,Sun Liang1,Yang Zhi1,Qu Yuanyuan1,Tong Nanyang1,Sun Caixing1,Xia Liang1

Affiliation:

1. Zhejiang Cancer Hospital, Chinese Academy of Sciences

Abstract

Abstract Background: Brain metastases are crucial in cancer progression, requiring focused efforts on the screening, early detection, and treatment. However, accurately forecasting the postoperative prognosis of patients with non-small cell lung cancer brain metastasis remains a challenge. This retrospective study aims to discern the factors that influence the prognosis of such patients. Patients and materials: A total of 151 cases from Zhejiang Cancer Hospital were collected. Univariate analysis was conducted using Kaplan-Meier and Log-rank test, while multivariate analysis was performed using Cox proportional hazards regression model. Student’s t-test and chi-square test were employed to examine the differences between the long-term survival and the short-term survival groups. Ultimately, a predictive model was constructed by using R 4.2.1. Results: Univariate analysis identified 12 factors as prognostic factors, showing statistical significance. In multivariate analysis, the primary contributing factors to survival were identified as age, chemotherapy of brain metastases, pathology, surgery of non-small cell lung cancer, targeted drugs, and GPA score. Compared long-term and short-term groups, age, pathology, surgery of lung, targeted therapy, and radiotherapy of brain metastases were statistically differentiating factors. Based on multivariate analysis, we established a clinical predictive model predicting 2-year, 3-year, and 5-year survival rates. Conclusion: Younger age, receiving chemotherapy for brain metastases, adenocarcinoma pathology, lung cancer surgery, targeted therapy, and a high GPA score are associated with longer survival. This model predicts the survival period for patients with non-small cell lung cancer brain metastasis after surgery and helps in selecting more effective treatment plans.

Publisher

Research Square Platform LLC

Reference24 articles.

1. Epidemiology of brain metastases and leptomeningeal disease;Lamba N;Neuro Oncol,2021

2. Wang Y, Chen R, Wa Y, Ding S, Yang Y, Liao J, Tong L, Xiao G. Tumor Immune Microenvironment and Immunotherapy in Brain Metastasis From Non-Small Cell Lung Cancer. Front Immunol., Tyagi PMC, Wu A, Watabe SY. K. Metabolism in the progression and metastasis of brain tumors. Cancer Lett. 2022;539:215713. doi: 10.1016/j.canlet.2022.215713. Epub 2022 May 2. PMID: 35513201; PMCID: PMC9999298.

3. Narita Y, Sato S, Kayama T. Review of the diagnosis and treatment of brain metastases. Jpn J Clin Oncol. 2022;52(1):3–7. 10.1093/jjco/hyab182. PMID: 34865060.

4. Surgery for brain metastases-impact of the extent of resection;Winther RR;Acta Neurochir (Wien),2022

5. Cebula H, Todeschi J, Le Fèvre C, Antoni D, Ollivier I, Chibbaro S, Noël G, Proust F. Quelle est la place de la chirurgie dans la prise en charge des métastases cérébrales en 2020 [What is the place of surgery in the management of brain metastases in 2020]. Cancer Radiother. 2020;24(6–7):470–476. French. 10.1016/j.canrad.2020.05.008. Epub 2020 Aug 6. PMID: 32773281.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3